BMI, tobacco, and alcohol: Roles in glaucoma progression examined in study

News
Article

The primary findings were that a higher BMI was protective against glaucoma progression and use of tobacco and alcohol were not significantly associated with retinal nerve fiber layer change.

Man holding cigarette and whiskey glass at table Image credit: AdobeStock/Parkin

Image credit: AdobeStock/Parkin

A newly published study1 found that use of tobacco and alcohol did not significantly affect the rate of change of the retinal nerve fiber layer (RNFL), while a high body mass index (BMI) was associated with slower structural changes in the visual fields, according to Asmaa A. Youssif, MD, from the Duke Eye Center, Duke University, Durham, NC, and the Department of Ophthalmology, Assiut University Faculty of Medicine, Assiut, Egypt.

Youssif and colleagues explained that while studies of obesity and tobacco and alcohol consumption showed that many chronic diseases are affected by the factors being studied, none had mentioned an effect on glaucoma progression.

In light of that gap in the medical literature, the researchers set out to determine how the RNFL fared over time in patients with glaucoma in association with the BMI and tobacco and alcohol use.

A total of 2,839 eyes (1,584 patients) with glaucoma from the Duke Ophthalmic Registry were included. All patients had undergone at least 2 spectral-domain optical coherency tomography (SD-OCT) tests over a minimum 6-month follow-up.

Information about alcohol and tobacco use was obtained from electronic health records and the mean BMI was calculated.

The authors reported that the mean follow-up time was 4.7±2.1 years and each eye had undergone a mean of 5.1±2.2 SD-OCT tests. A history of tobacco or alcohol consumption was reported by 43% and 54% of patients, respectively, and 34% of patients were obese.

The primary findings were that a higher BMI was protective against glaucoma progression (0.014 µm/year slower per each 1 kg/m2 higher; p=0.011), and use of tobacco and alcohol were not significantly associated with RNFL change rates (p=0.473 and p=0.471, respectively). Patients who were had significantly faster rates of structural loss (−0.768 µm/year; p=0.002) compared with those who had a normal weight.

Reference:
  1. Youssif AA, Onyekaba N-A, Naithani R, et al. Social history and glaucoma progression: the effect of body mass index, tobacco and alcohol consumption on the rates of structural change in patients with glaucoma, Br J Ophthalmol. 2024;108:1694-1700.
Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
© 2025 MJH Life Sciences

All rights reserved.